- PR Newswire•last month
BOULDER, Colo., Dec. 8, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced that following the approval from shareholders at the 2016 Annual Meeting of Shareholders of the proposal to change ...
- Capital Cube•2 months ago
Categories: Yahoo Finance Get free summary analysis Venaxis, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Venaxis, Inc. – Vermillion, Inc., Chembio Diagnostics, Inc., OraSure Technologies, Inc., Alere Inc., Echo Therapeutics, Inc., American Bio Medica Corporation and Myriad Genetics, Inc. (VRML-US, CEMI-US, OSUR-US, ALR-US, ECTE-US, ... Read more (Read more...)
- PR Newswire•4 months ago
CASTLE ROCK, Colo., Sept. 23, 2016 /PRNewswire/ -- Venaxis®, Inc. (APPY), announced that on September 21, 2016, the Company approved the grant of stock options to six new employees, hired in connection with the Company's acquisition of BiOptix Diagnostics, Inc., to purchase an aggregate of 95,000 shares of common stock. The stock options were granted as inducement grants material to the new employees entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).
APPY : Summary for Venaxis, Inc. - Yahoo Finance
Bioptix, Inc. (APPY)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||3.62 - 4.04|
|52 Week Range||1.60 - 6.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.11|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|